A phase 1b dose expansion study of the pan-Class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin...

Por Smyth, Lillian M., Monson, Kelsey R., Jhaveri, Komal, Drilon, Alexander, Li, Bob T, Abida, Wassim, Iyer, Gopa, Gerecitano, John F., Gounder, Mrinal, Harding, James J., Voss, Martin H., Makker, Vicky, Ho, Alan L., Razavi, Pedram, Iasonos, Alexia, Bialer, Philip, Lacouture, Mario E., Teitcher, Jerrold B., Erinjeri, Joseph P., Katabi, Nora, Fury, Matthew G., Hyman, David M.
Publicado no Invest New Drugs (2017)

AKT Inhibition in Solid Tumors With AKT1 Mutations

Por Hyman, David M., Smyth, Lillian M., Donoghue, Mark T.A., Westin, Shannon N., Bedard, Philippe L., Dean, Emma J., Bando, Hideaki, El-Khoueiry, Anthony B., Pérez-Fidalgo, José A., Mita, Alain, Schellens, Jan H.M., Chang, Matthew T., Reichel, Jonathan B., Bouvier, Nancy, Selcuklu, S. Duygu, Soumerai, Tara E., Torrisi, Jean, Erinjeri, Joseph P., Ambrose, Helen, Barrett, J. Carl, Dougherty, Brian, Foxley, Andrew, Lindemann, Justin P.O., McEwen, Robert, Pass, Martin, Schiavon, Gaia, Berger, Michael F., Chandarlapaty, Sarat, Solit, David B., Banerji, Udai, Baselga, José, Taylor, Barry S.
Publicado no J Clin Oncol (2017)